EUVIMEDEUVIMED entdecken
Crossref

Pembrolizumab therapy leads to resolution of lentigines and tumour control in a patient with xeroderma pigmentosum and advanced cutaneous squamous cell carcinoma

Magí Brufau-Cochs iD, Sofia Gómez-Martínez iD, Francisco Aya, Laura Serra-García, Susana Puig, Josep Malvehy, Sebastian Podlipnik

Clinical and Experimental Dermatology · 26.05.2026 · 51 (6) · 1101-1103

DOI: 10.1093/ced/llag029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 22.01.2026. Verfasst von Magí Brufau-Cochs und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Clinic Barcelona, Barcelona, Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: European Commission, Carlos III Health Institute, TV3 La Marató Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We describe a 54-year-old patient with xeroderma pigmentosum (XP) who developed unresectable cutaneous squamous cell carcinoma and was treated with pembrolizumab, an immune checkpoint inhibitor (ICI). The treatment led to significant tumour regression and, unexpectedly, a complete resolution of the patient’s lentigines, while vitiligo and other pigmented lesions remained unchanged. The findings suggest that ICIs may amplify immune responses against ultraviolet-induced pigmented lesions in patients with XP, potentially linked to the disease’s high mutational burden. Further studies are needed to elucidate the underlying mechanisms.

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Clinic Barcelona, Barcelona, Spain.
  • Department of Medical Oncology, Hospital Clinic Barcelona, Barcelona, Spain.
  • August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • Spanish Network for Rare Diseases, Carlos III Health Institute, Barcelona, Spain.
  • Department of Medicine, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.

ORCID-Profile: Magí Brufau-Cochs, Sofia Gómez-Martínez

Förderung

  • European Commission
  • Carlos III Health Institute
  • TV3 La Marató Foundation

Zitieren

APA

Brufau-Cochs, M., Gómez-Martínez, S., Aya, F., Serra-García, L., Puig, S., Malvehy, J., & Podlipnik, S. (2026). Pembrolizumab therapy leads to resolution of lentigines and tumour control in a patient with xeroderma pigmentosum and advanced cutaneous squamous cell carcinoma. Clinical and Experimental Dermatology, 51(6), 1101-1103. https://doi.org/10.1093/ced/llag029

Vancouver

Brufau-Cochs M, Gómez-Martínez S, Aya F, Serra-García L, Puig S, Malvehy J, et al. Pembrolizumab therapy leads to resolution of lentigines and tumour control in a patient with xeroderma pigmentosum and advanced cutaneous squamous cell carcinoma. Clinical and Experimental Dermatology. 2026;51(6):1101-1103. doi:10.1093/ced/llag029

BibTeX
@article{BrufauCochs2026,
  author = {Brufau-Cochs, Magí and Gómez-Martínez, Sofia and Aya, Francisco and Serra-García, Laura and Puig, Susana and Malvehy, Josep and Podlipnik, Sebastian},
  title = {Pembrolizumab therapy leads to resolution of lentigines and tumour control in a patient with xeroderma pigmentosum and advanced cutaneous squamous cell carcinoma},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  volume = {51},
  number = {6},
  pages = {1101--1103},
  doi = {10.1093/ced/llag029}
}
Kostenlos starten →